Meredith C. Fisher, PhD, MBA, is the Co-founding CEO and Director of Violet Therapeutics, a preclinical-stage biotechnology company developing first-in-class therapies for neurodegenerative diseases by mapping cell-to-cell signaling interactions in the brain.

Meredith earned a PhD in Molecular Microbiology from Harvard University, an MBA from MIT Sloan School of Management, and an undergraduate degree from Mount Holyoke College, and while at Harvard she co-founded Harvard Graduate Women in Science and Engineering (HGWISE).

Meredith previously served as a Partner at Mass General Brigham Ventures, an early-stage life science VC firm, where she co-founded multiple portfolio companies including three as founding CEO.

Prior to Violet Therapeutics, Meredith co-founded and served as CEO of Mediar Therapeutics, advancing innovative antibodies targeting fibrosis through Phase 2 clinical studies, and has held board seats across six biotech companies including Brave Bio, Claris Bio, Falcon Therapeutics, and Sena Therapeutics.

Violet Therapeutics has raised over $15M in seed funding from investors including the Dementia Discovery Fund, UTEC, and Lifespan Vision Ventures, with its CONNECT platform and lead EphB3 program targeting synaptic preservation to address Alzheimer's and other neurodegenerative diseases.